Sydney Lupkin
👤 SpeakerAppearances Over Time
Podcast Appearances
It expands coverage to some but not all Medicare beneficiaries with obesity.
They have to have additional health conditions or a body mass index over 35.
People with Medicare will be able to get them for a copay of $50 a month.
State Medicaid programs will have to opt in, but the lower cost of the drugs to the government, $245 per patient per month, is something that I'm hearing will likely push them toward this.
Novo Nordisk and Eli Lilly's blockbuster obesity and type 2 diabetes drugs are the centerpiece of agreements announced by the White House.
The drugs, Ozempic, Wegovy, Zepound, and Manjaro, will be available to the government at lower prices and to Medicare beneficiaries for a $50 copay.
The deals expand Medicare and Medicaid access for some but not all patients with obesity, and the arrangements would expand discounts available to patients buying the drugs through TrumpRx.gov, a website that is expected to launch before the end of the year.
The companies also promised that if experimental obesity pills they are developing win FDA approval, they will cost $149 per month for their starting doses.
Novo Nordisk and Eli Lilly's blockbuster obesity and type 2 diabetes drugs are the centerpiece of agreements announced by the White House.
The drugs, Ozempic, Wegovy, Zepound, and Manjaro, will be available to the government at lower prices and to Medicare beneficiaries for a $50 copay.
The deals expand Medicare and Medicaid access for some but not all patients with obesity, and the arrangements would expand discounts available to patients buying the drugs through TrumpRx.gov, a website that is expected to launch before the end of the year.
The companies also promised that if experimental obesity pills they are developing win FDA approval, they will cost $149 per month for their starting doses.
Normally, companies can't advertise a drug to treat a condition it hasn't been FDA approved to treat.
But sponsored search results online aren't regulated the way television ads are.
Daniel Eisenkraft-Klein and his colleagues at Harvard Medical School looked at two years of paid search results for Ozempic.
According to a study published in JAMA Network Open, 11% of paid search phrases contain the word wait, even though Ozempic is only approved to treat type 2 diabetes.
Novo Nordisk says its paid search approach is standard and in compliance with U.S.